UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN

College of Veterinary Medicine
Veterinary Teaching Hospital
240 Small Animal Clinic, MC-004
1008 W. Hazelwood Drive
Urbana, IL 61802-4714

Funded Study: Funded study for canine patients with splenic hemangiosarcoma.

Study Title: Suppression of extracellular glutamate efflux and mGluR1 signaling to impede canine hemangiosarcoma cell growth.

Purpose of Study/Background/Objectives: The purpose of this study is to evaluate if novel adjuvant treatments riluzole and sulfasalazine, 2 oral drugs already approved by the FDA can be safely combined with surgery and doxorubicin for improving the long-term outcomes in dogs with splenic hemangiosarcoma. The objective of this trial is to distinguish the toxicity profiles of these combined treatments and determine a difference in biological activity if one exists in pet dogs receiving treatment.

Inclusion Criteria: To be eligible for participation in this study, the patient must have a diagnosis of splenic hemangiosarcoma diagnosed by histopathology. The patient must be in good overall condition and have no other serious illness. Additionally, the patient may not have received prior chemotherapy or radiation treatment and cannot be on any form of non-steroidal anti-inflammatory drug for 2 weeks prior to study entry.

Exclusion Criteria:

- Metastatic disease
- Poor prognosis/ill
- Certain cardiac diseases

Eligibility Diagnostics: Prior to study entry, pet owners will be charged an initial consultation feel and be financially responsible and required to have the following diagnostics performed on their dog:

- Diagnosis of hemangiosarcoma with histopathology
- 3 view chest xrays
- Abdominal Ultrasound
- Screening blood work and urinalysis

Treatment/Protocol: The canine patient will be treated with combination of 2 oral drugs (riluzole [escalating dose] and sulfasalazine [fixed dose]) and conventional therapy inclusive of splenectomy and systemic chemotherapy (doxorubicin IV x 5 cycles). On scheduled revisits, dogs will be restaged with bloodwork, thoracic radiographs and abdominal ultrasound.

Owner Commitments: Qualified dogs will receive IV doxorubicin every 2 weeks for 5 treatments. Oral riluzole and sulfasalazine will be administered twice daily at home. Dogs and owners will be required to visit the study site for regularly scheduled appointments and document study associated observations and questionnaires as appropriate. After the completion of IV chemotherapy, patients will be restaged every two months until progression of disease.

Compensation: Pet owners are financially responsible for all diagnostics to deem their pet eligible for study recruitment such as, initial exam, CBC, chem, UA, thoracic radiographs, abdominal ultrasound. In addition, the pet owner is also responsible for surgery(splenectomy) to remove the tumor. After the patient has been deemed eligible the clinical trial will cover the cost of treatment and recheck appointments.

Contact Information: We would be happy to provide you with additional information regarding the study. Please reach out to Rebecca Kamerer at rmoss81@illinois.edu or 217-300-6453.

.